Hologic Inc (HOLX)
76.35
+0.44
(+0.58%)
USD |
NASDAQ |
Mar 18, 16:00
76.33
-0.02
(-0.03%)
After-Hours: 20:00
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 17.92B |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | -0.93% |
Valuation | |
PE Ratio | 36.18 |
PE Ratio (Forward) | Upgrade |
PS Ratio | 4.732 |
Price to Book Value | 3.851 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.5501 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 46.24% |
Profile
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (60% of total sales, boosted by pandemic), breast health (14% of sales, suppressed by pandemic), surgical (11%), and skeletal health (1%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts. |
URL | http://www.hologic.com |
Investor Relations URL | https://investors.hologic.com |
HQ State/Province | Massachusetts |
Sector | Healthcare |
Industry | Medical Instruments & Supplies |
Equity Style | Mid Cap/Blend |
Next Earnings Release | May. 01, 2024 (est.) |
Last Earnings Release | Feb. 01, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (60% of total sales, boosted by pandemic), breast health (14% of sales, suppressed by pandemic), surgical (11%), and skeletal health (1%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts. |
URL | http://www.hologic.com |
Investor Relations URL | https://investors.hologic.com |
HQ State/Province | Massachusetts |
Sector | Healthcare |
Industry | Medical Instruments & Supplies |
Equity Style | Mid Cap/Blend |
Next Earnings Release | May. 01, 2024 (est.) |
Last Earnings Release | Feb. 01, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |